1 July 2016

Pan Pacific raises £1.1m

25/11/09 Robert Tyerman

Battle-scarred Pan Pacific Aggregates (PPA) says it should start granite production before January after raising £1.1 million at a discounted 0.5p.

Based in British Columbia and quoted on AIM, PPA, which is emerging from a series of setbacks and upheavals, is now in a position to move its Pumptown granite quarry into production this quarter, declares managing director William Voaden. KC Investments, a vehicle for City dealer Keith Catchpole, has taken nearly a fifth of the placing and VSA Capital, an investment firm headed by Voaden, has been granted warrants to subscribe for 0.7 per cent of the enlarged capital at 0.5p over three years.

Floated in 2005 at 88p, PPA shares collapsed all the way to 0.25p after its original project ran into local opposition and then Pumptown was bedevilled with logistical and infrastructure problems and the company fell out with its local partners. These hurdles have mostly now been overcome and PPA directors talk of target production of one million tonnes a year from Pumptown, with hoped-for gross margins of 2.65p a tonne and a chance to supply regional infrastructure projects, some related to the 2010 Vancouver Winter Olympics.

Now 0.68p, the shares have speculative potential.

Please click here to complete our investment survey. You will automatically be entered into a prize draw to win two return tickets to Paris.

Tags: AIM, Fundraisings

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

The robots are coming 01/07/16

Recent AIM newcomer Blue Prism (AIM: PRSM) has released a promising set of maiden results for the half year to April. Revenues grew by a handy 21 per cent and momentum seems to be accelerating with 33 new customers added to the 57 in place at the end of October. 

Avingtrans returns cash and remains a Buy 30/06/16

Having turned most of its market cap into cash through the sale of its aerospace division, it’s no surprise that Avingtrans (AIM: AVG) has been a very defensive stock during the recent turmoil. We now have some more details on the return of cash to shareholders which was promised as part of the disposal.

Omega investing in growth 28/06/16

Omega Diagnostics results looked positive and highlighted the progress being made in getting important new products to market. The investment to support those efforts will depress profits this year; but the market seems willing to look through this with Omega being a rare stock to be trading above its pre-Brexit level.

Stadium hit by profit warning 23/06/16

Stadium Group shares have been hit by a profit warning. This is a particular blow given the company’s progress in repositioning itself into a higher quality, design-led business.

Verona raises £42m to fund drug trials  19/06/16

Verona Pharma (AIM: VRP) has raised an impressive £42 million net of costs which will fund phase II trials for its RPL554 compound. This drug targets severe respiratory diseases, in particular the 65 million worldwide sufferers from COPD (chronic obstructive pulmonary disease).

Income attractions at Belvoir 15/06/16

It’s fair to say that buy-to-let landlords have been under George Osborne’s cosh. He’s introduced a raised stamp duty rate and withdrawn higher-rate tax relief. However, Belvoir Lettings has seen little change in the market as far as its core lettings agency business is concerned. Furthermore, the shares have responded positively to a major acquisition which makes Belvoir the largest UK lettings agent.

More News